Buy & Sell Summit Therapeutics Inc (SMMT) – Summit Therapeutics Inc Price Today
Aura AI Summary
Key Stats
- $10.92BMarket Cap
- HealthSector
- -50.53%3M Drawdown
- $10.34BEnterprise Value
- -Dividend Yield
- 9 daysTypical Hold Time
Summit Therapeutics Inc (SMMT) is currently valued at a market capitalization of $10.92B, with an enterprise value of $10.34B. Over the past 52 weeks, Summit Therapeutics Inc has traded between a low of $13.05 and a high of $29.32, highlighting its annual price range. Over the past three months, Summit Therapeutics Inc has recorded a drawdown of -50.53%, reflecting recent price volatility. On average, investors hold Summit Therapeutics Inc for approximately 9 days, indicating typical investor behavior on the platform.
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Most Recent News
Investigation launched into Gildan Activewear over alleged revenue inflation and financial engineering.
Bronstein, Gewirtz & Grossman, LLC has opened an investigation into Gildan Activewear following a report accusing the company of inflating revenues by channel stuffing and obscuring financial details through off-balance sheet receivables. The report ...

Infineon wins patent case, stops Innoscience from selling infringing GaN products in Germany
The Munich District Court ruled in favor of Infineon Technologies, prohibiting Chinese company Innoscience from manufacturing, selling, and marketing products that infringe Infineon's patented gallium nitride (GaN) technology in Germany. This marks I...

Amazon plans to sell AI Trainium chips beyond AWS, expanding its AI infrastructure reach.
Amazon is expanding its AI chip strategy by planning to sell its custom Trainium AI chips outside of Amazon Web Services (AWS), targeting third-party data centers. This move aims to compete with NVIDIA in the AI infrastructure market and meets growin...
